A Booster Vaccine for CAR-T Cells
Exclusively Licensed
Invention type: Technology
/
Case number: #19933H
The disclosure describes amphiphilic ligand conjugates comprising a chimeric antigen receptor (CAR) ligand, a lipid (diacyl lipid), a linker (hydrophilic polymers, hydrophilic amino acids, polysaccharides), compositions and methods of using the constructs are claimed, for example, to stimulate proliferation of CAR expressing cells.
Researchers
Darrell J Irvine
/
Leyuan Ma
Technology Areas: Chemicals & Materials: Polymers / Therapeutics: Cell Based Therapy, Proteins & Antibodies
Impact Areas: Healthy Living
-
compositions for chimeric antigen receptor t cell therapy and uses thereof
Hong Kong | Published application -
compositions for chimeric antigen receptor t cell therapy and uses thereof
Australia | Pending -
compositions for chimeric antigen receptor t cell therapy and uses thereof
Canada | Published application -
compositions for chimeric antigen receptor t cell therapy and uses thereof
China | Published application -
compositions for chimeric antigen receptor t cell therapy and uses thereof
European Patent Convention | Published application -
compositions for chimeric antigen receptor t cell therapy and uses thereof
Japan | Granted | 7,654,240 -
compositions for chimeric antigen receptor t cell therapy and uses thereof
Korea (south) | Published application -
compositions for chimeric antigen receptor t cell therapy and uses thereof
Mexico | Granted | 426,727 -
compositions for chimeric antigen receptor t cell therapy and uses thereof
New Zealand | Pending -
compositions for chimeric antigen receptor t cell therapy and uses thereof
Russian Federation | Granted | 2,819,805 -
compositions for chimeric antigen receptor t cell therapy and uses thereof
Japan | Published application -
compositions for chimeric antigen receptor t cell therapy and uses thereof
New Zealand | Pending -
compositions for chimeric antigen receptor t cell therapy and uses thereof
Mexico | Published application -
compositions for chimeric antigen receptor t cell therapy and uses thereof
United States of America | Published application
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.